Multicenter Study of Factors Associated with Visual and Anatomic Outcomes of Suprachoroidal Hemorrhage.

IF 2.1 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2025-09-05 DOI:10.1097/IAE.0000000000004670

Tianyu Liu, Sahal Saleh, Jason Keil, Revati Rashingkar, Yinxi Yu, Gui-Shuang Ying, George A Williams, Alexander J Brucker, Benjamin J Kim

{"title":"Multicenter Study of Factors Associated with Visual and Anatomic Outcomes of Suprachoroidal Hemorrhage.","authors":"Tianyu Liu, Sahal Saleh, Jason Keil, Revati Rashingkar, Yinxi Yu, Gui-Shuang Ying, George A Williams, Alexander J Brucker, Benjamin J Kim","doi":"10.1097/IAE.0000000000004670","DOIUrl":null,"url":null,"abstract":"Purpose: To report outcomes of suprachoroidal hemorrhage (SCH).Methods: Retrospective non-randomized study of eyes with SCH from two sites (1/1/2013-12/31/2022). The primary outcome was the 6-month change in visual acuity (VA). Multivariable analysis was performed, as well as a comparison of matched eyes with and without systemic steroids.Results: 143 eyes of 143 patients (mean age 70.8 years, 52.4% male) were included, with 72 perioperative, 24 traumatic, and 47 spontaneous SCH cases. The mean (SD) presenting VA was 2.07 (0.92) logMAR. 87 (60.8%) were managed non-surgically, 24 (16.8%) underwent drainage, and 32 (22.4%) underwent drainage and vitrectomy; 36 (25.2%) received systemic steroids. At 6 months, the mean (SD) change in VA from presentation was -0.41 (0.84) logMAR. 102 (71.3%) eyes achieved anatomic success (complete retinal attachment). Concurrent RD was associated with worse VA change and anatomic success in multivariable analysis (P < 0.05). In the matching analysis, eyes receiving systemic steroids were more likely to achieve ≥ 3-line gain in VA than matched eyes without systemic steroids (77.8% vs 55.3%, P = 0.047).Conclusion: The visual prognosis of eyes with SCH remains guarded. Systemic steroids may be associated with a modest benefit for visual outcomes. Concurrent RD portends worse outcomes.","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004670","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To report outcomes of suprachoroidal hemorrhage (SCH).

Methods: Retrospective non-randomized study of eyes with SCH from two sites (1/1/2013-12/31/2022). The primary outcome was the 6-month change in visual acuity (VA). Multivariable analysis was performed, as well as a comparison of matched eyes with and without systemic steroids.

Results: 143 eyes of 143 patients (mean age 70.8 years, 52.4% male) were included, with 72 perioperative, 24 traumatic, and 47 spontaneous SCH cases. The mean (SD) presenting VA was 2.07 (0.92) logMAR. 87 (60.8%) were managed non-surgically, 24 (16.8%) underwent drainage, and 32 (22.4%) underwent drainage and vitrectomy; 36 (25.2%) received systemic steroids. At 6 months, the mean (SD) change in VA from presentation was -0.41 (0.84) logMAR. 102 (71.3%) eyes achieved anatomic success (complete retinal attachment). Concurrent RD was associated with worse VA change and anatomic success in multivariable analysis (P < 0.05). In the matching analysis, eyes receiving systemic steroids were more likely to achieve ≥ 3-line gain in VA than matched eyes without systemic steroids (77.8% vs 55.3%, P = 0.047).

Conclusion: The visual prognosis of eyes with SCH remains guarded. Systemic steroids may be associated with a modest benefit for visual outcomes. Concurrent RD portends worse outcomes.

查看原文本刊更多论文

脉络膜上出血视觉及解剖结果相关因素的多中心研究。

目的：报道脉络膜上出血（SCH）的预后。方法：回顾性非随机研究两个部位（2013年1月1日- 2022年12月31日）的SCH眼。主要观察指标为6个月视力变化（VA）。进行了多变量分析，并比较了使用和不使用全身类固醇的匹配眼睛。结果：143例患者143只眼（平均年龄70.8岁，男性52.4%），围手术期72例，外伤性24例，自发性47例。VA的平均（SD）为2.07 (0.92)logMAR。非手术治疗87例（60.8%），引流24例（16.8%），引流+玻璃体切除32例（22.4%）；36例（25.2%）接受全身性类固醇治疗。6个月时，VA的平均（SD）变化为-0.41 (0.84)logMAR。102只（71.3%）眼解剖成功（视网膜完全附着）。在多变量分析中，并发RD与较差的VA改变和解剖成功相关（P < 0.05）。在配对分析中，接受全身类固醇治疗的眼睛比未接受全身类固醇治疗的眼睛更有可能获得≥3线的VA增益（77.8% vs 55.3%, P = 0.047）。结论：SCH眼的视力预后仍需谨慎。全身性类固醇可能对视力结果有一定的益处。并发RD预示着更糟糕的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.